Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer. (1st March 2021)

• Record Type: Journal Article
• Authors: Zhang, Tao; Wu, Bihan; Akakuru, Ozioma Udochukwu; Yao, Chenyang; Sun, Shan; Chen, Libin; Ren, Wenzhi; Wu, Aiguo; Huang, Pintong
• Is Part Of: Cancer letters. Volume 500(2021)
• Page Start: 41
• Page End: 50
• Publication Date: 2021-03-01
• Subjects: Mitochondria-targeted -- Hsp90 inhibitor -- IR780 -- Mild-temperature -- Photothermal therapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2020.12.028
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Mitochondria-targeted mild-temperature photothermal therapy (MT-PTT) is a promising strategy that can maximize anticancer effects and reduce adverse reactions. Here, a novel photosensitizer with mitochondrial targeting based on IR780 iodide and heat shock protein 90 inhibitor (BIIB021), which can passively accumulate in MCF-7 cells and achieve effective MT-PTT effect is synthesized. The prepared PEG-IR780-BIIB021 nano-micelles possess considerable biocompatibility and biological stability, with an encapsulation efficiency of about 84% for BIIB021. They can selectively enrich in mitochondria, and release BIIB021 after NIR irradiation to reduce cell tolerance to heat, thereby reducing the mitochondrial membrane potential and rapidly affecting key intrinsic apoptotic factors (Cyt-C, Caspase-9, Bcl-2 and Bax) to achieve the effect of MT-PTT. It is believed that mitochondria-targeted MT-PTT generated by the PEG-IR780-BIIB021 nano-micelles is a promising therapeutic strategy in clinical practice. Highlights: Mitochondria-targeted mild-temperature PTT. High IR780 loading rate. Strong antitumor effect in HER2-positive breast tumors.